Tenderwize
Retour à la recherche

Pharmaceutical products with active substance Filgotinib (ATC: L04AF04)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Jan 30, 2027 · 155 days left·Open·Supplies
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Filgotinib (ATC: L04AF04)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No guarantee of sales volumes; discounts may not lead to significant revenue.

Contracts may be terminated early if exclusive contracts are tendered. The notice states that this is not a public proc...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for pharmaceutical products with active ingredient Filgotinib (ATC: L04AF04)
  • Open-house model with continuous enrollment
Afficher le résumé complet

This is an 'open-house' model for non-exclusive discount agreements on pharmaceutical products containing the active ingredient Filgotinib (ATC: L04AF04). The buyer is AOK Sachsen-Anhalt. Any qualified pharmaceutical company can join at any time under the same conditions. The contract duration is a maximum of 24 months, ending on 31 March 2027. The buyer explicitly states this is not a public procurement under EU Directive 2014/24/EU or German procurement law (GWB). No estimated value is provided. The notice includes some inconsistencies: structured data indicates no electronic submission, while the XML notice allows electronic submission via email with a qualified electronic signature; structured data marks it as EU-funded, but XML indicates no EU funds.

Risques

No guarantee of sales volumes; discounts may not lead to significant revenue.

Contracts may be terminated early if exclusive contracts are tendered. The notice states that this is not a public proc...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company or a consortium of pharmaceutical companies
  • Open-house model: no exclusivity, no individual negotiations

Administrative

  • Must request and submit fully completed and signed participation documents

Critères d'attribution

Lot 1

No specific award criteria; any qualified participant is accepted.

Acheteur

Localisation

Magdeburg, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE258393558

Activité

Health

Lots (1)

LOT-0001

Pharmaceutical products with active substance Filgotinib (ATC: L04AF04)

Non-exclusive discount agreement for finished medicinal products containing Filgotinib (ATC L04AF04). Open to all interested pharmaceutical companies that meet participation requirements. No exclusivity, no individual negotiations. Contract start as early as 1 April 2025, maximum 24 months, ending 31 March 2027. The buyer reserves the right to terminate these agreements if exclusive contracts are tendered later.

SuppliesEU fundedElectronic submission

Localisation

DEE03, Germany

Durée

2 YEAR

Catégorie

Pharmaceutical products

Critères d'attribution

No specific award criteria; any qualified participant is accepted.

Détails de la procédure

Date de publication
18 Feb 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
110003-2025

Documents (1)

Appels d'offres similaires